These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 27411674)

  • 1. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
    Saha RN; Pahan K
    Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases.
    Selvi BR; Cassel JC; Kundu TK; Boutillier AL
    Biochim Biophys Acta; 2010; 1799(10-12):840-53. PubMed ID: 20833281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of Tip60 HAT mediated neural histone acetylation homeostasis is an early common event in neurodegenerative diseases.
    Beaver M; Bhatnagar A; Panikker P; Zhang H; Snook R; Parmar V; Vijayakumar G; Betini N; Akhter S; Elefant F
    Sci Rep; 2020 Oct; 10(1):18265. PubMed ID: 33106538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities.
    Pirooznia SK; Elefant F
    Front Cell Neurosci; 2013; 7():30. PubMed ID: 23543406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
    Jiang H; Jia D; Tang B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration.
    Ganai SA; Ramadoss M; Mahadevan V
    Curr Neuropharmacol; 2016; 14(1):55-71. PubMed ID: 26487502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
    Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HAT and HDAC: Enzyme with Contradictory Action in Neurodegenerative Diseases.
    Singh R; Rathore AS; Dilnashin H; Keshri PK; Gupta NK; Prakash SAS; Zahra W; Singh S; Singh SP
    Mol Neurobiol; 2024 Nov; 61(11):9110-9124. PubMed ID: 38587698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory.
    Mahgoub M; Monteggia LM
    Learn Mem; 2014 Oct; 21(10):564-8. PubMed ID: 25227251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.
    Mai A; Rotili D; Valente S; Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3940-57. PubMed ID: 19751207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases in memory and cognition.
    Penney J; Tsai LH
    Sci Signal; 2014 Dec; 7(355):re12. PubMed ID: 25492968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of altered protein acetylation in neurodegenerative disease.
    Kabir F; Atkinson R; Cook AL; Phipps AJ; King AE
    Front Aging Neurosci; 2022; 14():1025473. PubMed ID: 36688174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.
    Rossaert E; Pollari E; Jaspers T; Van Helleputte L; Jarpe M; Van Damme P; De Bock K; Moisse M; Van Den Bosch L
    Acta Neuropathol Commun; 2019 Jul; 7(1):107. PubMed ID: 31277703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.